Clinical Trials Browser

Phase 2 × Completed × eltrombopag × Clear all

Anemia, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Chronic

NCT01168921 2023-03-23

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

23 enrolled 9 charts

Classical hematologyLymphoidOther hematologic neoplasm

Jacobs syndrome, Leukemia, Thrombocytopenia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01893372 2020-02-18

Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Phase 2 Completed

29 enrolled 12 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT01890746 2019-09-11

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Phase 2 Completed

148 enrolled 42 charts

Classical hematologyOther hematologic neoplasm

Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT01610180 2018-07-16

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Phase 2 Completed

18 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Purpura, Thrombocytopenic, Idiopathic

NCT01440374 2017-06-05

ASPIRE

Phase 2 Completed

162 enrolled 24 charts

Classical hematologyMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT00102726 2017-03-23

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

Phase 2 Completed

183 enrolled

Classical hematology

Jacobs syndrome, Thrombocytopenia

NCT01488565 2016-02-15

Aza-E

Phase 2 Completed

25 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Clinical Trials

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

ASPIRE

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

Aza-E